SCHEMBL14978271

SCHEMBL14978271

O=C1NCc2cc(Br)c(O)c(F)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.34
PIM1 P11309 2/20 0.34
ROCK1 Q13464 2/20 0.34
CLK4 Q9HAZ1 2/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK5 Q00535 1/20 0.34
DYRK1A Q13627 1/20 0.34
LRRK2 Q5S007 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
CISD1 Q9NZ45 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
KDR P35968 2/20 0.32
HSP90AB1 P08238 1/20 0.32
CDK1 P06493 1/20 0.32
ROCK2 O75116 1/20 0.32
ABCC9 O60706 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201440 0.80 AURKA (0.34) AURKAPIM1ROCK1CLK4PIK3CD
SCHEMBL5311516 0.74 AURKA (0.37) AURKAPIM1ROCK1CLK4CSNK1A1
SCHEMBL23089173 0.74 GRM5 (0.37) AURKAPIM1ROCK1CLK4CSNK1A1
SCHEMBL29987052 0.70 MKNK2 (0.41) AURKAPIM1ROCK1CLK4PIK3CD
SCHEMBL1476404 0.70 MKNK2 (0.41) AURKAPIM1ROCK1CLK4CSNK1A1
SCHEMBL24667786 0.70 MKNK2 (0.41) AURKAPIM1ROCK1CLK4PIK3CD
SCHEMBL4729863 0.70 AURKA (0.44) AURKAPIM1ROCK1CLK4DYRK1B
SCHEMBL10200890 0.70 AURKA (0.34) AURKAKDRCDK1CA12CA9
SCHEMBL32666473 0.70 GAA (0.43) PIM1MAOAMAOBKDRABCC9
SCHEMBL25302444 0.68 KDR (0.41) AURKAPIM1ROCK1CLK4CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450355-B2 Compounds for the treatment of inflammatory diseases MERCK SHARP & DOHME CORP. (US) 2013-05-28 US disclosed
US-8450355-B2 Compounds for the treatment of inflammatory diseases MERCK SHARP & DOHME CORP. (US) 2013-05-28 US disclosed
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES SCHERING CORPORATION (US) 2011-11-24 US disclosed
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES SCHERING CORPORATION (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, ADAMTS13, MMP11 AURKA 1956/4885PIM1 4393/4885ROCK1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.